Drug Trial Radar · NCT02216214
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
Last checked: Nov 20, 2026Latest source record: Nov 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
888
Actual
Start
Oct 7, 2014
Primary completion
Nov 29, 2017
Study completion Jan 2, 2018
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Aug 13, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.
Conditions
- Overactive Bladder (OAB)
Interventions
MirabegronDrug
oral tablet
PlaceboDrug
oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to End of Treatment (EOT) in Mean Number of Micturitions Per 24 HoursTime frame: Baseline and EOT (up to 12 weeks)
- Change From Baseline to EOT in Mean Number of Incontinence Episodes Per 24 HoursTime frame: Baseline and EOT (up to 12 weeks)
Locations
120 sites in 2 countries. Site status is shown where the registry gives one.
Site US00066
Huntsville, Alabama
Site US00148
Mobile, Alabama
Site US00009
Anchorage, Alaska
Site US00020
Tucson, Arizona
Site US00019
Tucson, Arizona
Site US00063
Little Rock, Arkansas
Site US00081
Little Rock, Arkansas
Site US00176
Anaheim, California
Site US00048
Beverly Hills, California
Site US00142
Beverly Hills, California
Site US00150
Hawaiian Gardens, California
Site US00112
Los Angeles, California
Site US00034
Los Angeles, California
Site US00010
Murrieta, California
Site US00135
San Diego, California
Site US00139
San Diego, California
Site US00144
Santa Maria, California
Site US00083
Stanford, California
Site US00026
Colorado Springs, Colorado
Site US00039
Denver, Colorado
Site US00004
Denver, Colorado
Site US00040
New London, Connecticut
Site US00090
Washington D.C., District of Columbia
Site US00064
Brooksville, Florida
Site US00080
Coral Gables, Florida
Site US00002
DeBary, Florida
Site US00001
DeLand, Florida
Site US00017
DeLand, Florida
Site US00018
Edgewater, Florida
Site US00027
Fleming Island, Florida
Site US00151
Hialeah, Florida
Site US00179
Jupiter, Florida
Site US00057
Kissimmee, Florida
Site US00076
Lakeland, Florida
Site US00037
Miami, Florida
Site US00029
Miami, Florida
Site US00042
Miami, Florida
Site US00007
North Miami, Florida
Site US00021
Pompano Beach, Florida
Site US00035
Port Orange, Florida
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.